Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Ex VP & Chief Commerc. Officer | March 17, 2023 | March 21, 2023 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP & Chief Commercial Officer | November 18, 2019 | November 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 17, 2023 · Filed March 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,073 |
Ending reported balance
After 2023-03-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-17 · Sale · Disposed 2,520 · Balance 57,948 F1: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units ("RSUs") granted on March 11, 2022 for 16,000 shares. Row 2 · 2023-03-17 · Sale · Disposed 1,875 · Balance 56,073 F2: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 12, 2021 for 11,875 shares. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.07 to $1.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units ("RSUs") granted on March 11, 2022 for 16,000 shares.
F2: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 12, 2021 for 11,875 shares.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.07 to $1.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
RIGEL PHARMACEUTICALS INC
Report date November 18, 2019 · Filed November 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 · Expires 2028-01-24 | Direct | 75,000 |
Reported balance
After 2019-11-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-18 · Grant · Acquired 75,000 · Balance 75,000 F1: The reporting person was granted a performance based option to purchase 75,000 shares of common stock on January 24, 2018. Thus,the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted a performance based option to purchase 75,000 shares of common stock on January 24, 2018. Thus,the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2023 Filed Mar 21, 2023 21:00 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 1,875 | $1.07 | $2,007.56 |
DisclosureSEC source: 0001140361-23-012884 · form4.xml · nonDerivative · entry 2 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,073 F2 · shares: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 12, 2021 for 11,875 shares. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.07 to $1.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 21:00 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 2,520 | $1.07 | $2,696.40 |
DisclosureSEC source: 0001140361-23-012884 · form4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,948 F1 · shares: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units ("RSUs") granted on March 11, 2022 for 16,000 shares. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:49 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 98,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001140361-23-010158 · form4.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: . The option vests in 48 equal monthly installments commencing on the grant date of March 1, 2023, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:25 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001567619-23-001474 · doc1.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2033-01-26 F1 · derivative.exercise_date: The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date. The option vests in full upon a change in control of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 14, 2022 21:21 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 1,657 | $5.60 | $9,274.73 |
DisclosureSEC source: 0001567619-22-006947 · doc1.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,468 F1 · shares: These shares were sold by the reporting person in a pre-elected sell-to-cover transaction to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 14, 2022 for 3,959 shares. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 98,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001140361-22-009260 · form4.xml · derivative · entry 2 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires 2032-03-10 F2 · derivative.exercise_date: The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-009260 · form4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,125 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 20:59 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 1,560 | $4.95 | $7,722.16 |
DisclosureSEC source: 0001567619-22-001050 · doc1.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,125 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on January 31, 2020 for 7,500 shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.95 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 16:32 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001567619-21-014220 · doc1.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-07-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months measured from July 29, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:31 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 71,250 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001209191-21-020588 · doc4.xml · derivative · entry 2 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 71,250 shares Expires 2031-03-11 F2 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 12, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:31 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 11,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020588 · doc4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,685 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest in three equal annual installments measured from March 12, 2021. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 18:10 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 1,690 | $11.68 | $19,739.20 |
DisclosureSEC source: 0001209191-21-003040 · doc4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,810 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on January 31, 2020 for 7,500 shares. Read SEC document |
| January 31, 2020 Filed Jan 31, 2020 19:33 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option ( Right to Buy) · Derivative | 150,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001209191-20-005872 · doc4.xml · derivative · entry 2 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-01-30 F2 · derivative.exercise_date: The option vests as follows: 25% of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 6, 2020, with the remaining shares to vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| January 31, 2020 Filed Jan 31, 2020 19:33 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005872 · doc4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · shares: Represents shares underlying Restricted Stock Units award that vest according to the following schedule: 50% shares will vest on the first anniversary of the vesting commencement date of January 6, 2020, and the remaining 50% shares will vest on the second anniversary of the vesting commencement date. Read SEC document |
| January 24, 2020 Filed Jan 30, 2020 16:44 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 5,000 | $13.52 | $67,602.50 |
DisclosureSEC source: 0001209191-20-005548 · doc4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Ex VP & Chief Commerc. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 01:15 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-011942 · edgar.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-24 F1 · derivative.exercise_price: The reporting person was granted a performance based option to purchase 75,000 shares of common stock on January 24, 2018. Thus,the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. F1 · derivative.exercise_date: The reporting person was granted a performance based option to purchase 75,000 shares of common stock on January 24, 2018. Thus,the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 22:00 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option ( Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001209191-19-021282 · doc4.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-03-20 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 21, 2019 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 23:23 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-004208 · edgar.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: On January 24, 2018, the reporting person was granted a performance based option to purchase 75,000 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:36 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000935 · edgar.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 14:26 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 4,000 | $10.21 | $40,840.00 |
DisclosureSEC source: 0001209191-18-060345 · doc4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $10.00 to $10.37 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1 to this Form 4. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 20:51 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 7,500 | $9.92 | $74,407.50 |
DisclosureSEC source: 0001209191-18-060179 · doc4.xml · nonDerivative · entry 2 Mayer Eldon C. III · CIK 0001686952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.77 to $10.09 inclusive. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 20:51 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 7,500 | $9.75 | $73,143.00 |
DisclosureSEC source: 0001209191-18-060179 · doc4.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.57 to $9.99 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 2 and 3 to this Form 4. Read SEC document |
| September 11, 2018 Filed Sep 12, 2018 23:48 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | PurchaseCommon Stock | 50,000 | $3.23 | $161,340.00 |
DisclosureSEC source: 0001179110-18-011343 · edgar.xml · nonDerivative · entry 2 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 F2 · price: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transaction ranging from $3.19 to $3.27. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each separate price. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 23:48 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | PurchaseCommon Stock | 50,000 | $3.28 | $164,210.00 |
DisclosureSEC source: 0001179110-18-011343 · edgar.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 F1 · price: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transaction ranging from $3.26 to $3.31. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each separate price. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 23:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | PurchaseCommon Stock | 100,000 | $2.82 | $282,320.00 |
DisclosureSEC source: 0001179110-18-010936 · edgar.xml · nonDerivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 F1 · price: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions ranging from $2.78 to $2.86 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each such separate price. F2 · balance_after: Includes 15,000 shares that were purchased by the Reporting Person under the Issuer's Employee Stock Purchase Plan, in increments of 5,000 shares, on June 30, 2017, December 29, 2017 and June 29, 2018. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-18-006680 · edgar.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: On February 2, 2017 the reporting person was granted an option to purchase 50,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On May 9, 2018, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:24 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-18-020455 · doc4.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-13 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 14, 2018 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 23:33 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-18-001143 · edgar.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2018. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 18:11 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $13.70 | $0.00 |
DisclosureSEC source: 0001209191-18-003012 · doc4.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-04 F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months measured from January 5, 2018, subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 00:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-17-001821 · edgar.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The shares vest monthly over four (4) years from January 1, 2017. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 00:44 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001179110-16-030655 · edgar.xml · derivative · entry 1 Mayer Eldon C. III · CIK 0001686952 · EVP &Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-10-10 F1 · derivative.exercise_date: Common Stock subject to the Option shall vest over a four-year term, with one-fourth of the shares subject to the Option vesting on October 10, 2017, and 1/48th of the shares subject to the Option vesting monthly thereafter, subject to the Continuous Service (as defined in the Plan) to the Company through each vesting date. Read SEC document |
| November 28, 2001 Filed Nov 28, 2018 20:51 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 6,000 | $10.07 | $60,447.00 |
DisclosureSEC source: 0001209191-18-060179 · doc4.xml · nonDerivative · entry 3 Mayer Eldon C. III · CIK 0001686952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.7495 to $10.26 inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.